| No. |
Company's Name |
Technology |
Details |
| 105 |
JINIS Biopharmaceuticals Co. |
Antiobesity Biodrug JBD301 |
|
| 104 |
JW CreaGene Corp. |
Drug Delivery Technology Using CTP (Cytoplasmic Transduction Peptide) |
|
| 103 |
JW CreaGene Corp. |
Regulatory Dendritic Cell-Based Rheumatoid Arthritis Vaccine Technology |
|
| 102 |
JW CreaGene Corp. |
Dendritic Cell-Based Cancer Vaccine Technology |
|
| 101 |
JW Pharmaceutical |
|
|
| 100 |
JW_pharmaceutical |
Global development of CWP232291, a novel cancer drug targeting Wnt/beta-catenin signaling |
|
| 99 |
KCNB Bio |
|
|
| 98 |
KIST |
A PHARMACEUTICAL COMPOSITION CONTAINING DAURINOL FOR THE PREVENTION AND TREATMENT OF CANCERS |
|
| 97 |
KOLMAR KOREA |
|
|
| 96 |
Korea Basic Science Institute |
CUPID (Cell-based Un-/identified Protein Interaction Discovery) |
|
| 95 |
Korea Institute of Science and Technology |
Cell Aggregate-Hydrogel-Polymer Scaffold Complex for Cartilage Regeneration, Method for the Preparat |
|
| 94 |
Korea Otsuka Pharmaceutical Co., Ltd. |
|
|
| 93 |
Korea Research Institue of Chemical Technology |
Novel Substituted-1,1-Dioxo-Benzo[1,2,4] Thiadizin-3-Ones |
|
| 92 |
Korea Research Institue of Chemical Technology |
Method for Preparing Highly Optically Active 2-Sufonyloxy-1-Phenylethanol Derivatives |
|
| 91 |
Korea United Pharm, Inc. |
|
|
| 90 |
Korea United Pharm.Inc. |
Introducing The Sustained-Release Cilostazol Tablet of Once Daily 1 Tablet Regimen, Having Improved Releasing Rate And Reduced Side Effect |
|
| 89 |
Korea Univ. |
Use of TRIM72 as a Target For Muscle and Heart Enhancer |
|
| 88 |
Korea Univ. |
Use of Inhibitors of Leukotriene B4 Receptor BLT2 for Treating Human Cancers |
|
| 87 |
Kuhnil Pharmaceutical Co., Ltd |
|
|
| 86 |
Kukdong R&D Center(3D Materials) |
|
|
